Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus.

Autor:	Stephens LM; Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA., Ross KA; Department of Chemical and Biological Engineering, Iowa State University, Ames, IA.; Nanovaccine Institute, Ames, IA., Waldstein KA; Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA., Legge KL; Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA.; Nanovaccine Institute, Ames, IA.; Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.; Department of Pathology, University of Iowa, Iowa City, IA; and., McLellan JS; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX., Narasimhan B; Department of Chemical and Biological Engineering, Iowa State University, Ames, IA.; Nanovaccine Institute, Ames, IA., Varga SM; Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA; varga@uiowa.edu.; Nanovaccine Institute, Ames, IA.; Department of Microbiology and Immunology, University of Iowa, Iowa City, IA.; Department of Pathology, University of Iowa, Iowa City, IA; and.
Jazyk:	angličtina
Zdroj:	Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2021 May 01; Vol. 206 (9), pp. 2122-2134. Date of Electronic Publication: 2021 Apr 07.
DOI:	10.4049/jimmunol.2100018
Abstrakt:	Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in both young children and in older adults. Despite the morbidity, mortality, and high economic burden caused by RSV worldwide, no licensed vaccine is currently available. We have developed a novel RSV vaccine composed of a prefusion-stabilized variant of the fusion (F) protein (DS-Cav1) and a CpG oligodeoxynucleotide adjuvant encapsulated within polyanhydride nanoparticles, termed RSVNanoVax. A prime-boost intranasal administration of RSVNanoVax in BALB/c mice significantly alleviated weight loss and pulmonary dysfunction in response to an RSV challenge, with protection maintained up to at least 6 mo postvaccination. In addition, vaccinated mice exhibited rapid viral clearance in the lungs as early as 2 d after RSV infection in both inbred and outbred populations. Vaccination induced tissue-resident memory CD4 and CD8 T cells in the lungs, as well as RSV F-directed neutralizing Abs. Based on the robust immune response elicited and the high level of durable protection observed, our prefusion RSV F nanovaccine is a promising new RSV vaccine candidate. (Copyright © 2021 by The American Association of Immunologists, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu